CoChat

Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833

Chico, Isagani, Kang, Min H., Bergan, Raymond, Abraham, Jame, Bakke, Susan, Meadows, Beverly, Rutt, Ann, Robey, Rob, Choyke, Peter, Merino, Maria, Goldspiel, Barry, Smith, Tom, Steinberg, Seth, Figg, William D., Fojo, Tito, Bates, Susan · 2001 · Journal of Clinical Oncology
Cited by 90

The DOI matches its Crossref record.

Abstract

PURPOSE: PSC 833 (valspodar) is a second-generation P-glycoprotein (Pgp) antagonist developed to reverse multidrug resistance. We conducted a phase I study of a 7-day oral administration of PSC 833 in combination with paclitaxel, administered as a 96-hour continuous infusion. PATIENTS AND METHODS: Fifty patients with advanced cancer were enrolled onto the trial. PSC 833 was administered orally for 7 days, beginning 72 hours before the start of the paclitaxel infusion. Paclitaxel dose reductions were planned because of the pharmacokinetic interactions known to occur with PSC 833. RESULTS: In combination with PSC 833, maximum-tolerated doses were defined as paclitaxel 13.1 mg/m 2/d continuous intravenous infusion (CIVI) for 4 days without filgrastim, and paclitaxel 17.5 mg/m 2/d CIVI for 4 days with filgrastim support. Dose-limiting toxicity for the combination was neutropenia. Statistical analysis of cohorts revealed similar mean steady-state concentrations (C pss) and areas under the concentration-versus-time curve (AUCs) when patients received paclitaxel doses of 13.1 or 17.5 mg/m 2/d for 4 days with PSC 833, as when they received a paclitaxel dose of 35 mg/m 2/d for 4 days without PSC 833. However, the effect of PSC 833 on paclitaxel pharmacokinetics varied greatly among individual patients, although a surrogate assay using CD56+ cells suggested inhibition of Pgp was complete or nearly complete at low concentrations of PSC 833. Responses occurred in three of four patients with non–small-cell lung cancer, and clinical benefit occurred in five of 10 patients with ovarian carcinoma. CONCLUSION: PSC 833 in combination with paclitaxel can be administered safely to patients provided the paclitaxel dose is reduced to compensate for the pharmacokinetic interaction. Surrogate studies with CD56+ cells indicate that the maximum-tolerated dose for PSC 833 gives serum levels much higher than those required to block Pgp. The variability in paclitaxel pharmacokinetics, despite complete inhibition of Pgp in the surrogate assay, suggests that other mechanisms, most likely related to P450, contribute to the pharmacokinetic interaction. Future development of combinations such as this should include strategies to predict pharmacokinetics of the chemotherapeutic agent. This in turn will facilitate dosing to achieve comparable CPss and AUCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2001.19.3.832

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 90

Metadata

Authors
Chico, I., Kang, M. H., Bergan, R., Abraham, J., Bakke, S., Meadows, B., Rutt, A., Robey, R., Choyke, P., Merino, M., Goldspiel, B., Smith, T., Steinberg, S., Figg, W. D., Fojo, T., & Bates, S.
Venue
Journal of Clinical Oncology
Published
2001-02-01
Volume
19
Issue
3
Pages
832-842
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1926017027
Cited by
90
References
0
FWCI
3.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833. https://app.cochat.ai/papers/10.1200/jco.2001.19.3.832
The paper
Chico, I., Kang, M. H., Bergan, R., Abraham, J., Bakke, S., Meadows, B., Rutt, A., Robey, R., Choyke, P., Merino, M., Goldspiel, B., Smith, T., Steinberg, S., Figg, W. D., Fojo, T., & Bates, S. (2001). Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2001.19.3.832

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.